


MGL-3196

04/20

ALTERNATE NAMES: Resmetirom; VIA-3196; 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile; 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile; 1,2,4-Triazine-6-carbonitrile; 2-(3,5-dichloro-4-[[6-hydroxy-5-(propan-2-yl)pyridazin-3-yl]oxy]phenyl)-5-hydroxy-3-oxo-2,3-dihydro-1,2,4-triazine-6-carbonitrile

CATALOG #: B3010-5 5 mg
B3010-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₇H₁₂Cl₂N₆O₄

MOLECULAR WEIGHT: 435.2

CAS NUMBER: 920509-32-6

APPEARANCE: Light yellow powder

PURITY: 98%

SOLUBILITY: ~20 mg/ml in DMSO and DMF
~1 mg/ml in Ethanol

DESCRIPTION: A selective thyroid hormone receptor β agonist with EC₅₀ values of 0.21 and 3.74 μ M for THR β and THR α , respectively. It significantly lowers non-HDL-C and liver TG in hypercholesterolemic rat and rabbit models at doses where there is no effect on TSH levels or the central thyroid axis. It significantly decreased LDL-C by up to 30%, and showed a statistical trend to reduce TG up to 60% in healthy volunteers, at once daily oral dose of 50 mg or higher for 2 weeks. It does not show THR- α mediated gene expression in a rat heart model indicating low potential for cardiac adverse effects. *In vitro* assays are predictive of lower off target actions. It shows an IC₂₀ of ~30 μ M for blockage of the hERG channel and IC₅₀ >50 μ M for CYP3A4/5 and CYP2C19. Formulations containing MGL-3196 are in clinical trials for the treatment of dyslipidemia.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Kelly, M.J., Pietranico-Cole, S., Larigan, J.D., et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia. *J. Med. Chem.* 57(10), 3912-3923 (2014).

RELATED PRODUCTS:

27-Hydroxycholesterol (Cat. No. B2988)
 Lovastatin (Cat. No. 1692)
 K-604, ACAT-1 inhibitor (Cat. No. B2926)
 ProbucoI (Cat. No. B2968)
 Simvastatin (Cat. No. 1693)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**